Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28500830 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL9396585 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL9559491 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL28525482 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL28099107 | 0.92 | CA2 (0.54) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL11806278 | 0.90 | GPR84 (0.61) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL159858 | 0.90 | GPR84 (0.61) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL5054302 | 0.90 | GPR84 (0.61) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL161181 | 0.90 | GPR84 (0.61) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL11171767 | 0.90 | GPR84 (0.61) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| CN-107802623-B | Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders | 开曼化学股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| CN-106748951-B | Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions | 开曼化学股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2020-07-02 | — | — | US | disclosed |
| EP-3176162-B1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-2875022-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2015-05-27 | — | — | EP | disclosed |
| CN-104640542-A | Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders | CAYMAN CHEMICAL CO INC | 2015-05-20 | — | — | CN | disclosed |
| WO-2015009991-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144500-A2 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014015246-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015247-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| EP-1773802-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006011047-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060020022-A1 | Enantioselective separation method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | GPR84 20/4885FFAR1 75/4885MAPT 3228/4885 |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | GPR84 20/4885FFAR1 75/4885MAPT 3228/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | GPR84 20/4885FFAR1 75/4885MAPT 3228/4885 |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | PTGER4, PTGER1, PTGIR | GPR84 21/4885FFAR1 60/4885MAPT 2798/4885 |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | GPR84 21/4885FFAR1 60/4885MAPT 2798/4885 |
| US-20060020022-A1 | Enantioselective separation method | SLC7A1, SLC10A1, DHCR7 | GPR84 2190/4885FFAR1 76/4885MAPT 3454/4885 |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | GPR84 20/4885FFAR1 75/4885MAPT 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.